nach oben

Cancer and Metastasis Reviews

Erschienen in:

28.11.2023 | REVIEW

Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance

verfasst von: Aliye Tabatabaee, Behjat Nafari, Armin Farhang, Amirali Hariri, Arezoo Khosravi, Ali Zarrabi, Mina Mirian

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

This comprehensive review explores vimentin as a pivotal therapeutic target in cancer treatment, with a primary focus on mitigating metastasis and overcoming drug resistance. Vimentin, a key player in cancer progression, is intricately involved in processes such as epithelial-to-mesenchymal transition (EMT) and resistance mechanisms to standard cancer therapies. The review delves into diverse vimentin inhibition strategies. Precision tools, including antibodies and nanobodies, selectively neutralize vimentin's pro-tumorigenic effects. DNA and RNA aptamers disrupt vimentin-associated signaling pathways through their adaptable binding properties. Innovative approaches, such as vimentin-targeted vaccines and microRNAs (miRNAs), harness the immune system and post-transcriptional regulation to combat vimentin-expressing cancer cells. By dissecting vimentin inhibition strategies across these categories, this review provides a comprehensive overview of anti-vimentin therapeutics in cancer treatment. It underscores the growing recognition of vimentin as a pivotal therapeutic target in cancer and presents a diverse array of inhibitors, including antibodies, nanobodies, DNA and RNA aptamers, vaccines, and miRNAs. These multifaceted approaches hold substantial promise for tackling metastasis and overcoming drug resistance, collectively presenting new avenues for enhanced cancer therapy.

Pérez-González, A., Bévant, K., & Blanpain, C. (2023). Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nature Cancer, 4(8), 1063–1082. https://doi.org/10.1038/s43018-023-00595-yCrossRefPubMedPubMedCentral

Torborg, S. R., Li, Z., Chan, J. E., & Tammela, T. (2022). Cellular and molecular mechanisms of plasticity in cancer. Trends in Cancer, 8(9), 735–746. https://doi.org/10.1016/j.trecan.2022.04.007CrossRefPubMedPubMedCentral

Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021). Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nature Medicine, 27(2), 212–224. https://doi.org/10.1038/s41591-021-01233-9CrossRefPubMed

Greaves, M., & Maley, C. C. (2012). Clonal evolution in cancer. Nature, 481(7381), 306–313. https://doi.org/10.1038/nature10762CrossRefPubMedPubMedCentral

Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., et al. (2023). Tumor heterogeneity: preclinical models, emerging technologies, and future applications. [Review]. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1164535

Zhou, H., Tan, L., Liu, B., & Guan, X.-Y. (2023). Cancer stem cells: Recent insights and therapies. Biochemical Pharmacology, 209, 115441. https://doi.org/10.1016/j.bcp.2023.115441CrossRefPubMed

Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., et al. (2020). Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies. [Review]. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01280.

Quan, Q., Wang, X., Lu, C., Ma, W., Wang, Y., Xia, G., et al. (2020). Cancer stem-like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion. Cancer Science, 111(2), 467–476. https://doi.org/10.1111/cas.14285CrossRefPubMedPubMedCentral

Ayob, A. Z., & Ramasamy, T. S. (2018). Cancer stem cells as key drivers of tumour progression. Journal of Biomedical Science, 25(1), 20. https://doi.org/10.1186/s12929-018-0426-4CrossRefPubMedPubMedCentral

10.

Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021). Drug resistance and Cancer stem cells. Cell Communication and Signaling: CCS, 19(1), 19. https://doi.org/10.1186/s12964-020-00627-5CrossRefPubMedPubMedCentral

11.

Bakir, B., Chiarella, A. M., Pitarresi, J. R., & Rustgi, A. K. (2020). EMT, MET, plasticity, and tumor metastasis. Trends in Cell Biology, 30(10), 764–776. https://doi.org/10.1016/j.tcb.2020.07.003CrossRefPubMedPubMedCentral

12.

Akhmetkaliyev, A., Alibrahim, N., Shafiee, D., & Tulchinsky, E. (2023). EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: The two sides of the same coin? Molecular Cancer, 22(1), 90. https://doi.org/10.1186/s12943-023-01793-zCrossRefPubMedPubMedCentral

13.

Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019). Cellular plasticity in cancer. Cancer Discovery, 9(7), 837–851. https://doi.org/10.1158/2159-8290.Cd-19-0015CrossRefPubMedPubMedCentral

14.

Shen, S., & Clairambault, J. (2020). Cell plasticity in cancer cell populations. F1000Research, 9, F1000 Faculty Rev-635. https://doi.org/10.12688/f1000research.24803.1

15.

Aanen, D. K., & Debets, A. J. M. (2019). Mutation-rate plasticity and the germline of unicellular organisms. Proceedings of the Royal Society B: Biological Sciences, 286(1902), 20190128. https://doi.org/10.1098/rspb.2019.0128CrossRefPubMedCentral

16.

Wu, S., Du, Y., Beckford, J., & Alachkar, H. (2018). Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia. Journal of Translational Medicine, 16(1), 170. https://doi.org/10.1186/s12967-018-1539-yCrossRefPubMedPubMedCentral

17.

Kuburich, N. A., den Hollander, P., Pietz, J. T., & Mani, S. A. (2022). Vimentin and cytokeratin: Good alone, bad together. Seminars in Cancer Biology, 86(Pt 3), 816–826. https://doi.org/10.1016/j.semcancer.2021.12.006CrossRefPubMed

18.

Liu, C. Y., Lin, H. H., Tang, M. J., & Wang, Y. K. (2015). Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget, 6(18), 15966–15983. https://doi.org/10.18632/oncotarget.3862CrossRefPubMedPubMedCentral

19.

Berr, A. L., Wiese, K., dos Santos, G., Koch, C. M., Anekalla, K. R., Kidd, M., et al. (2023). Vimentin is required for tumor progression and metastasis in a mouse model of non–small cell lung cancer. Oncogene, 42(25), 2074–2087. https://doi.org/10.1038/s41388-023-02703-9CrossRefPubMedPubMedCentral

20.

Usman, S., Waseem, N. H., Nguyen, T. K. N., Mohsin, S., Jamal, A., Teh, M.-T., et al. (2021). Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers, 13(19), 4985.PubMedPubMedCentral

21.

Chen, Z., Fang, Z., & Ma, J. (2021). Regulatory mechanisms and clinical significance of vimentin in breast cancer. Biomedicine & Pharmacotherapy, 133, 111068. https://doi.org/10.1016/j.biopha.2020.111068CrossRef

22.

Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., et al. (2020). Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduction and Targeted Therapy, 5(1), 228. https://doi.org/10.1038/s41392-020-00313-5CrossRefPubMedPubMedCentral

23.

Huang, Y., Hong, W., & Wei, X. (2022). The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology & Oncology, 15(1), 129. https://doi.org/10.1186/s13045-022-01347-8CrossRef

24.

Lindsey, S., & Langhans, S. A. (2014). Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Frontiers in Oncology, 4, 358. https://doi.org/10.3389/fonc.2014.00358CrossRefPubMedPubMedCentral

25.

Gonzalez, D. M., & Medici, D. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal, 7(344), re8. https://doi.org/10.1126/scisignal.2005189CrossRefPubMedPubMedCentral

26.

Zhu, C., Wei, Y., & Wei, X. (2019). AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications. Molecular Cancer, 18(1), 153. https://doi.org/10.1186/s12943-019-1090-3CrossRefPubMedPubMedCentral

27.

Tanaka, K., Tokunaga, E., Inoue, Y., Yamashita, N., Saeki, H., Okano, S., et al. (2016). Impact of expression of vimentin and Axl in breast cancer. Clinical Breast Cancer, 16(6), 520-526.e522. https://doi.org/10.1016/j.clbc.2016.06.015CrossRefPubMed

28.

Li, X. L., Liu, L., Li, D. D., He, Y. P., Guo, L. H., Sun, L. P., et al. (2017). Integrin β4 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Science and Reports, 7, 40464. https://doi.org/10.1038/srep40464CrossRef

29.

Masugi, Y., Yamazaki, K., Emoto, K., Effendi, K., Tsujikawa, H., Kitago, M., et al. (2015). Upregulation of integrin β4 promotes epithelial-mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Laboratory Investigation, 95(3), 308–319. https://doi.org/10.1038/labinvest.2014.166CrossRefPubMed

30.

Jaiswal, R. K., Varshney, A. K., & Yadava, P. K. (2018). Diversity and functional evolution of the plasminogen activator system. Biomedicine & Pharmacotherapy, 98, 886–898. https://doi.org/10.1016/j.biopha.2018.01.029CrossRef

31.

Wang, Q., Wang, Y., Zhang, Y., Zhang, Y., & Xiao, W. (2015). Involvement of urokinase in cigarette smoke extract-induced epithelial-mesenchymal transition in human small airway epithelial cells. Laboratory Investigation, 95(5), 469–479. https://doi.org/10.1038/labinvest.2015.33CrossRefPubMed

32.

Mauro, C. D., Pesapane, A., Formisano, L., Rosa, R., D’Amato, V., Ciciola, P., et al. (2017). Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Science and Reports, 7(1), 9388. https://doi.org/10.1038/s41598-017-10062-1CrossRef

33.

Skrypek, N., Bruneel, K., Vandewalle, C., De Smedt, E., Soen, B., Loret, N., et al. (2018). ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. Epigenetics & Chromatin, 11(1), 70. https://doi.org/10.1186/s13072-018-0239-4CrossRef

34.

Francart, M. E., Vanwynsberghe, A. M., Lambert, J., Bourcy, M., Genna, A., Ancel, J., et al. (2020). Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis. Oncogene, 39(18), 3680–3692. https://doi.org/10.1038/s41388-020-1244-1CrossRefPubMedPubMedCentral

35.

Duarte, S., Viedma-Poyatos, Á., Navarro-Carrasco, E., Martínez, A. E., Pajares, M. A., & Pérez-Sala, D. (2019). Vimentin filaments interact with the actin cortex in mitosis allowing normal cell division. Nature Communications, 10(1), 4200. https://doi.org/10.1038/s41467-019-12029-4CrossRefPubMedPubMedCentral

36.

An, J., Peng, C., Tang, H., Liu, X., & Peng, F. (2021). New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. International Journal of Molecular Sciences, 22(17). https://doi.org/10.3390/ijms22179644.

37.

Yang, Y., Li, Y., Yu, H., Ding, Z., Chen, L., Zeng, X., et al. (2023). Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics. Signal Transduction and Targeted Therapy, 8(1), 298. https://doi.org/10.1038/s41392-023-01518-0CrossRefPubMedPubMedCentral

38.

Jakobsen, K. R., Demuth, C., Sorensen, B. S., & Nielsen, A. L. (2016). The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Translational Lung Cancer Research, 5(2), 172–182.PubMedPubMedCentral

39.

Clement, M. S., Gammelgaard, K. R., Nielsen, A. L., & Sorensen, B. S. (2020). Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET -amplified EGFR-TKI resistant non-small cell lung cancer cells. Translational Lung Cancer Research, 9(5), 1904–1914.PubMedPubMedCentral

40.

Imani, S., Hosseinifard, H., Cheng, J., Wei, C., & Fu, J. (2016). Prognostic value of EMT-inducing transcription factors (EMT-TFs) in metastatic breast cancer: A systematic review and meta-analysis. Science and Reports, 6, 28587. https://doi.org/10.1038/srep28587CrossRef

41.

Horn, L. A., Fousek, K., & Palena, C. (2020). Tumor plasticity and resistance to immunotherapy. Trends Cancer, 6(5), 432–441. https://doi.org/10.1016/j.trecan.2020.02.001CrossRefPubMedPubMedCentral

42.

Gu, Y., Zhang, Z., & ten Dijke, P. (2023). Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cellular & Molecular Immunology, 20(4), 318–340. https://doi.org/10.1038/s41423-023-00980-8CrossRef

43.

Terry, S., Savagner, P., Ortiz-Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J. P., et al. (2017). New insights into the role of EMT in tumor immune escape. Molecular Oncology, 11(7), 824–846. https://doi.org/10.1002/1878-0261.12093CrossRefPubMedPubMedCentral

44.

Weng, C. H., Chen, L. Y., Lin, Y. C., Shih, J. Y., Lin, Y. C., Tseng, R. Y., et al. (2019). Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene, 38(4), 455–468. https://doi.org/10.1038/s41388-018-0454-2CrossRefPubMed

45.

Musaelyan, A., Lapin, S., Nazarov, V., Tkachenko, O., Gilburd, B., Mazing, A., et al. (2018). Vimentin as antigenic target in autoimmunity: A comprehensive review. Autoimmunity Reviews, 17(9), 926–934.PubMed

46.

Parry, D. A., Strelkov, S. V., Burkhard, P., Aebi, U., & Herrmann, H. (2007). Towards a molecular description of intermediate filament structure and assembly. Experimental Cell Research, 313(10), 2204–2216.PubMed

47.

Tang, D. D. (2008). Intermediate filaments in smooth muscle. American Journal of Physiology-Cell Physiology, 294(4), C869–C878.PubMed

48.

Kraxner, J., Lorenz, C., Menzel, J., Parfentev, I., Silbern, I., Denz, M., et al. (2021). Post-translational modifications soften vimentin intermediate filaments. Nanoscale, 13(1), 380–387.PubMed

49.

Mónico, A., Guzmán-Caldentey, J., Pajares, M. A., Martín-Santamaría, S., & Pérez-Sala, D. (2021). Elucidating vimentin interaction with zinc ions and its interplay with oxidative modifications through crosslinking assays and molecular dynamics simulations. bioRxiv, 2021.2002. 2012.430929.

50.

Danielsson, F., Peterson, M. K., Caldeira Araújo, H., Lautenschläger, F., & Gad, A. K. B. (2018). Vimentin diversity in health and disease. Cells, 7(10), 147.PubMedPubMedCentral

51.

Ostrowska-Podhorodecka, Z., & McCulloch, C. A. (2021). Vimentin regulates the assembly and function of matrix adhesions. Wound Repair and Regeneration, 29(4), 602–612.PubMed

52.

Tarbet, H. J., Dolat, L., Smith, T. J., Condon, B. M., O’Brien, E. T., III., Valdivia, R. H., et al. (2018). Site-specific glycosylation regulates the form and function of the intermediate filament cytoskeleton. elife, 7, e31807.PubMedPubMedCentral

53.

Robert, A., Hookway, C., & Gelfand, V. I. (2016). Intermediate filament dynamics: What we can see now and why it matters. BioEssays, 38(3), 232–243.PubMedPubMedCentral

54.

Eriksson, J. E., He, T., Trejo-Skalli, A. V., Härmälä-Braskén, A.-S., Hellman, J., Chou, Y.-H., et al. (2004). Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. Journal of Cell Science, 117(6), 919–932.PubMed

55.

Brennich, M. E., Vainio, U., Wedig, T., Bauch, S., Herrmann, H., & Köster, S. (2019). Mutation-induced alterations of intra-filament subunit organization in vimentin filaments revealed by SAXS. Soft Matter, 15(9), 1999–2008.PubMed

56.

Velez-delValle, C., Marsch-Moreno, M., Castro-Muñozledo, F., Galván-Mendoza, I. J., & Kuri-Harcuch, W. (2016). Epithelial cell migration requires the interaction between the vimentin and keratin intermediate filaments. Scientific Reports, 6(1), 1–10.

57.

Schietke, R., Bröhl, D., Wedig, T., Mücke, N., Herrmann, H., & Magin, T. M. (2006). Mutations in vimentin disrupt the cytoskeleton in fibroblasts and delay execution of apoptosis. European Journal of Cell Biology, 85(1), 1–10.PubMed

58.

Bornheim, R., Müller, M., Reuter, U., Herrmann, H., Büssow, H., & Magin, T. M. (2008). A dominant vimentin mutant upregulates Hsp70 and the activity of the ubiquitin-proteasome system, and causes posterior cataracts in transgenic mice. Journal of Cell Science, 121(22), 3737–3746.PubMed

59.

Müller, M., Bhattacharya, S. S., Moore, T., Prescott, Q., Wedig, T., Herrmann, H., et al. (2009). Dominant cataract formation in association with a vimentin assembly disrupting mutation. Human Molecular Genetics, 18(6), 1052–1057.PubMed

60.

Bang, H., Egerer, K., Gauliard, A., Lüthke, K., Rudolph, P. E., Fredenhagen, G., et al. (2007). Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis & Rheumatism, 56(8), 2503–2511.

61.

Cogné, B., Bouameur, J.-E., Hayot, G., Latypova, X., Pattabiraman, S., Caillaud, A., et al. (2020). A dominant vimentin variant causes a rare syndrome with premature aging. European Journal of Human Genetics, 28(9), 1218–1230.PubMedPubMedCentral

62.

Sharma, P., Alsharif, S., Fallatah, A., & Chung, B. M. (2019). Intermediate filaments as effectors of cancer development and metastasis: A focus on keratins, vimentin, and nestin. Cells, 8(5), 497.PubMedPubMedCentral

63.

Noh, H., Yan, J., Hong, S., Kong, L.-Y., Gabrusiewicz, K., Xia, X., et al. (2016). Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget, 7(44), 72021.PubMedPubMedCentral

64.

Steinmetz, N. F., Maurer, J., Sheng, H., Bensussan, A., Maricic, I., Kumar, V., et al. (2011). Two domains of vimentin are expressed on the surface of lymph node, bone and brain metastatic prostate cancer lines along with the putative stem cell marker proteins CD44 and CD133. Cancers, 3(3), 2870–2885.PubMedPubMedCentral

65.

Ramos, I., Stamatakis, K., Oeste, C. L., & Pérez-Sala, D. (2020). Vimentin as a multifaceted player and potential therapeutic target in viral infections. International Journal of Molecular Sciences, 21(13), 4675.PubMedPubMedCentral

66.

Suprewicz, Ł, Swoger, M., Gupta, S., Piktel, E., Byfield, F. J., Iwamoto, D. V., et al. (2022). Extracellular vimentin as a target against SARS-CoV-2 host cell invasion. Small (Weinheim an der Bergstrasse, Germany), 18(6), 2105640.

67.

Yu, Y.T.-C., Chien, S.-C., Chen, I.-Y., Lai, C.-T., Tsay, Y.-G., Chang, S. C., et al. (2016). Surface vimentin is critical for the cell entry of SARS-CoV. Journal of Biomedical Science, 23(1), 1–10.

68.

Amraei, R., Xia, C., Olejnik, J., White, M. R., Napoleon, M. A., Lotfollahzadeh, S., et al. (2022). Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells. Proceedings of the National Academy of Sciences, 119(6), e2113874119.

69.

Babic, I., Nurmemmedov, E., Yenugonda, V. M., Juarez, T., Nomura, N., Pingle, S. C., et al. (2018). Pritumumab, the first therapeutic antibody for glioma patients. Human Antibodies, 26(2), 95–101.PubMed

70.

Noh, H., Zhao, Q., Yan, J., Kong, L.-Y., Gabrusiewicz, K., Hong, S., et al. (2018). Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Letters, 433, 176–185.PubMedPubMedCentral

71.

Wang, C., Cigliano, A., Jiang, L., Li, X., Fan, B., Pilo, M. G., et al. (2015). 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice. Hepatology, 61(1), 200–213.PubMed

72.

van Beijnum, J. R., Huijbers, E. J., van Loon, K., Blanas, A., Akbari, P., Roos, A., et al. (2022). Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. Nature Communications, 13(1), 2842.PubMedPubMedCentral

73.

Yang, E. Y., & Shah, K. (2020). Nanobodies: Next generation of cancer diagnostics and therapeutics. Frontiers in Oncology, 10, 1182.PubMedPubMedCentral

74.

Zottel, A., Novak, M., Šamec, N., Majc, B., Colja, S., Katrašnik, M., et al. (2023). Anti-vimentin nanobody decreases glioblastoma cell invasion in vitro and in vivo. Cancers, 15(3), 573.PubMedPubMedCentral

75.

Zottel, A., Jovčevska, I., Šamec, N., Mlakar, J., Šribar, J., Križaj, I., et al. (2020). Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration. Therapeutic Advances in Medical Oncology, 12, 1758835920915302.PubMedPubMedCentral

76.

Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022). Cancer vaccines as promising immuno-therapeutics: Platforms and current progress. Journal of Hematology & Oncology, 15(1), 28. https://doi.org/10.1186/s13045-022-01247-xCrossRef

77.

van Loon, K., Huijbers, E. J. M., de Haan, J. D., & Griffioen, A. W. (2022). Cancer vaccination against extracellular vimentin efficiently adjuvanted with montanide ISA 720/CpG. Cancers (Basel), 14(11). https://doi.org/10.3390/cancers14112593

78.

Brentville, V. A., Metheringham, R. L., Gunn, B., Symonds, P., Daniels, I., Gijon, M., et al. (2016). Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T-cell-mediated antitumor immunity. Cancer Research, 76(3), 548–560. https://doi.org/10.1158/0008-5472.can-15-1085CrossRefPubMed

79.

Jiang, Z., Cui, Y., Wang, L., Zhao, Y., Yan, S., & Chang, X. (2013). Investigating citrullinated proteins in tumour cell lines. World Journal of Surgical Oncology, 11, 260. https://doi.org/10.1186/1477-7819-11-260CrossRefPubMedPubMedCentral

80.

Brentville, V. A., Metheringham, R. L., Daniels, I., Atabani, S., Symonds, P., Cook, K. W., et al. (2020). Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. Journal for ImmunoTherapy of Cancer, 8(1), https://doi.org/10.1136/jitc-2020-000560.

81.

Wang, V., & Wu, W. (2009). MicroRNA-based therapeutics for cancer. BioDrugs, 23(1), 15–23.PubMed

82.

Darzi, L., Boshtam, M., Shariati, L., Kouhpayeh, S., Gheibi, A., Mirian, M., et al. (2017). The silencing effect of miR-30a on ITGA4 gene expression in vitro: An approach for gene therapy. Research in Pharmaceutical Sciences, 12(6), 456–464. https://doi.org/10.4103/1735-5362.217426CrossRefPubMedPubMedCentral

83.

Naidu, S., Magee, P., & Garofalo, M. (2015). MiRNA-based therapeutic intervention of cancer. Journal of Hematology & Oncology, 8, 1–8.

84.

Kim, T. W., Lee, Y. S., Yun, N. H., Shin, C. H., Hong, H. K., Kim, H. H., et al. (2020). MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer. British Journal of Cancer, 123(7), 1123–1130.PubMedPubMedCentral

85.

Jimenez, L., Lim, J., Burd, B., Harris, T. M., Ow, T. J., Kawachi, N., et al. (2017). miR-375 regulates invasion-related proteins vimentin and L-plastin. The American Journal of Pathology, 187(7), 1523–1536.PubMedPubMedCentral

86.

Cheng, C.-W., Wang, H.-W., Chang, C.-W., Chu, H.-W., Chen, C.-Y., Yu, J.-C., et al. (2012). MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Research and Treatment, 134, 1081–1093.PubMed

87.

Bockhorn, J., Yee, K., Chang, Y.-F., Prat, A., Huo, D., Nwachukwu, C., et al. (2013). MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Research and Treatment, 137, 373–382.PubMed

88.

Arora, H., Qureshi, R., & Park, W.-Y. (2013). miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS ONE, 8(5), e64273.PubMedPubMedCentral

89.

Sun, Y., Hu, L., Zheng, H., Bagnoli, M., Guo, Y., Rupaimoole, R., et al. (2015). MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. The Journal of Pathology, 235(1), 25–36.PubMed

90.

Zhu, S., He, C., Deng, S., Li, X., Cui, S., Zeng, Z., et al. (2016). MiR-548an, transcriptionally downregulated by HIF1α/HDAC1, suppresses tumorigenesis of pancreatic cancer by targeting vimentin expression. Molecular Cancer Therapeutics, 15(9), 2209–2219.PubMed

91.

Yamasaki, T., Seki, N., Yamada, Y., Yoshino, H., Hidaka, H., Chiyomaru, T., et al. (2012). Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. International Journal of Oncology, 41(3), 805–817.PubMedPubMedCentral

92.

Yu, C., Wang, M., Chen, M., Huang, Y., & Jiang, J. (2015). Upregulation of microRNA-138-5p inhibits pancreatic cancer cell migration and increases chemotherapy sensitivity. Molecular Medicine Reports, 12(4), 5135–5140.PubMed

93.

Liu, X., Wang, C., Chen, Z., Jin, Y., Wang, Y., Kolokythas, A., et al. (2011). MicroRNA-138 suppresses epithelial–mesenchymal transition in squamous cell carcinoma cell lines. Biochemical Journal, 440(1), 23–31.PubMed

94.

Lee, J. W., Guan, W., Han, S., Hong, D. K., Kim, L. S., & Kim, H. (2018). Micro RNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer. Cancer Science, 109(5), 1404–1413.PubMedPubMedCentral

95.

Xu, Y., Yao, T., Huang, K., Liu, G., Huang, Y., Gao, J., et al. (2020). Circular RNA circTUBGCP3 Is up-regulated and promotes cell proliferation, migration and survivability via sponge mir-30b in osteosarcoma. OncoTargets and Therapy, 13, 3729.PubMedPubMedCentral

96.

Joglekar, M. V., Patil, D., Joglekar, V. M., Rao, G. V., Reddy, N. D., Mitnala, S., et al. (2009). The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets, 1(2), 137–147.PubMed

97.

Mao, L., Liu, S., Hu, L., Jia, L., Wang, H., Guo, M., et al. (2018). miR-30 family: a promising regulator in development and disease. BioMed Research International, 2018. https://doi.org/10.1155/2018/9623412

98.

Braun, J., Hoang-Vu, C., Dralle, H., & Hüttelmaier, S. (2010). Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene, 29(29), 4237–4244.PubMed

99.

Zhong, Z., Xia, Y., Wang, P., Liu, B., & Chen, Y. (2014). Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer. Molecular Medicine Reports, 10(5), 2575–2579.PubMed

100.

Liu, Z., Chen, L., Zhang, X., Xu, X., Xing, H., Zhang, Y., et al. (2014). RUNX 3 regulates vimentin expression via miR-30a during epithelial–mesenchymal transition in gastric cancer cells. Journal of Cellular and Molecular Medicine, 18(4), 610–623.PubMedPubMedCentral

101.

Zhang, Q., Mao, Z., & Sun, J. (2019). NF-κB inhibitor, BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a/NF-κB/Snail signaling in bladder cancer cells. Gene, 710, 91–97. https://doi.org/10.1016/j.gene.2019.04.039CrossRefPubMed

102.

Zhao, J. J., Lin, J., Zhu, D., Wang, X., Brooks, D., Chen, M., et al. (2014). miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Research, 74(6), 1801–1813. https://doi.org/10.1158/0008-5472.can-13-3311-tCrossRefPubMedPubMedCentral

103.

Qian, B.-J., You, L., Shang, F.-F., Liu, J., Dai, P., Lin, N., et al. (2015). Vimentin regulates neuroplasticity in transected spinal cord rats associated with micRNA138. Molecular Neurobiology, 51, 437–447.PubMed

104.

Bollong, M. J., Pietilä, M., Pearson, A. D., Sarkar, T. R., Ahmad, I., Soundararajan, R., et al. (2017). A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. Proceedings of the National Academy of Sciences, 114(46), E9903–E9912.

105.

Wu, J., Xie, Q., Liu, Y., Gao, Y., Qu, Z., Mo, L., et al. (2021). A small vimentin-binding molecule blocks cancer exosome release and reduces cancer cell mobility. Frontiers in Pharmacology, 12, 627394.PubMedPubMedCentral

106.

Li, Z., Wu, J., Zhou, J., Yuan, B., Chen, J., Wu, W., et al. (2021). A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseases. MBio, 12(5), e02542-e2521.PubMedPubMedCentral

107.

Bargagna-Mohan, P., Hamza, A., Kim, Y.-E., Ho, Y. K. A., Mor-Vaknin, N., Wendschlag, N., et al. (2007). The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chemistry & Biology, 14(6), 623–634.

108.

Thaiparambil, J. T., Bender, L., Ganesh, T., Kline, E., Patel, P., Liu, Y., et al. (2011). Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. International Journal of Cancer, 129(11), 2744–2755.PubMed

109.

Kaschula, C. H., Tuveri, R., Ngarande, E., Dzobo, K., Barnett, C., Kusza, D. A., et al. (2019). The garlic compound ajoene covalently binds vimentin, disrupts the vimentin network and exerts anti-metastatic activity in cancer cells. BMC Cancer, 19, 1–16.

110.

Yoon, S., Armstrong, B., Habib, N., & Rossi, J. J. (2017). Blind SELEX approach identifies RNA aptamers that regulate EMT and inhibit metastasis. Molecular Cancer Research, 15(7), 811–820. https://doi.org/10.1158/1541-7786.Mcr-16-0462CrossRefPubMed

111.

Zamay, T. N., Kolovskaya, O. S., Glazyrin, Y. E., Zamay, G. S., Kuznetsova, S. A., Spivak, E. A., et al. (2014). DNA-aptamer targeting vimentin for tumor therapy in vivo. Nucleic Acid Therapeutics, 24(2), 160–170. https://doi.org/10.1089/nat.2013.0471CrossRefPubMedPubMedCentral

112.

Rong, Y., Chen, H., Zhou, X. F., Yin, C. Q., Wang, B. C., Peng, C. W., et al. (2016). Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers. Oncotarget, 7(7), 8282–8294. https://doi.org/10.18632/oncotarget.6988CrossRefPubMedPubMedCentral

113.

Costello, A. M., Elizondo-Riojas, M. A., Li, X., Volk, D. E., Pillai, A. K., & Wang, H. (2021). Selection and characterization of vimentin-binding aptamer motifs for ovarian cancer. Molecules, 26(21), https://doi.org/10.3390/molecules26216525.

114.

Zamay, G. S., Kolovskaya, O. S., Zamay, T. N., Glazyrin, Y. E., Krat, A. V., Zubkova, O., et al. (2015). Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Molecular Therapy, 23(9), 1486–1496. https://doi.org/10.1038/mt.2015.108CrossRefPubMedPubMedCentral

115.

De La Fuente, A., Zilio, S., Caroli, J., Van Simaeys, D., Mazza, E. M. C., Ince, T. A., et al. (2020). Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy. Science Translational Medicine, 12(548), https://doi.org/10.1126/scitranslmed.aav9760.

116.

Costello, A. M., Elizondo-Riojas, M.-A., Li, X., Volk, D. E., Pillai, A. K., & Wang, H. (2021). Selection and characterization of vimentin-binding aptamer motifs for ovarian cancer. Molecules, 26(21), 6525.PubMedPubMedCentral

117.

Mirian, M., Khanahmad, H., Darzi, L., Salehi, M., & Sadeghi-Aliabadi, H. (2017). Oligonucleotide aptamers: Potential novel molecules against viral hepatitis. Research in Pharmaceutical Sciences, 12(2), 88–98. https://doi.org/10.4103/1735-5362.202447CrossRefPubMedPubMedCentral

118.

Wang, H., Li, X., Volk, D. E., Lokesh, G.L.-R., Elizondo-Riojas, M.-A., Li, L., et al. (2016). Morph-X-select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery. BioTechniques, 61(5), 249–259.PubMedPubMedCentral

119.

Zheng, Y., Zhang, J., Huang, M., Wang, T., Qu, X., Wu, L., et al. (2020). Selection of aptamers against vimentin for isolation and release of circulating tumor cells undergoing epithelial mesenchymal transition. Analytical Chemistry, 92(7), 5178–5184.PubMed

120.

121.

Jalalian, S. H., Ramezani, M., Abnous, K., & Taghdisi, S. M. (2018). Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo. Cancer Letters, 416, 87–93.PubMed

122.

Bahreyni, A., Yazdian-Robati, R., Hashemitabar, S., Ramezani, M., Ramezani, P., Abnous, K., et al. (2017). A new chemotherapy agent-free theranostic system composed of graphene oxide nano-complex and aptamers for treatment of cancer cells. International Journal of Pharmaceutics, 526(1–2), 391–399.PubMed

Titel: Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance
verfasst von: Aliye Tabatabaee
Behjat Nafari
Armin Farhang
Amirali Hariri
Arezoo Khosravi
Ali Zarrabi
Mina Mirian
Publikationsdatum: 28.11.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10154-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling

Sam68 is a druggable vulnerability point in cancer stem cells

Deciphering cellular plasticity in pancreatic cancer for effective treatments

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie